Expression, Purification, and Polyethylene Glycol Site-Specific Modification of Recombinant Human Interleukin 24 in Escherichia Coli

Overview

Journal Protein J

Publisher Springer

Specialty Biochemistry

Date 2019 May 8

PMID 31062210

Citations 2

Authors

Yao Zhang

Qunfeng Ma

Junfeng Wang

Jianlin Ge

Jilei Hua

Yinan Shi

Chi Zhang

Mengzhe Liu

Yuqi Wang

Zhinan Chen

Ziling Wang

Yongdong Liu

Hong Jiang

Affiliations

Soon will be listed here.

Abstract

Interleukin 24 (IL-24) has a broad spectrum of specific antitumor activities without affecting normal cells. The recombinant human IL-24 (rhIL-24) expressed in E. coli has low biological activity due to lack of necessary glycosylation modification. In this study, based on the modification of the non-glycosylated IL-24 with polyethylene glycol (PEG), we aimed to improve the stability and prolong its half-life in vivo. Firstly, the recombinant plasmid containing the hIL-24 cDNA was prepared by the prokaryotic-expression plasmid pET-28a and transformed into E. coli BL21. After induced by isopropyl β-D-thiogalactoside (IPTG), the target protein rhIL-24 was expressed as insoluble inclusion body, which was solubilized and denatured by 6 M guanidine hydrochloride. The denatured rhIL-24 was diluted to refold in the optimized buffer overnight at the protein concentration of 0.1 mg/mL. The refolded rhIL-24 was mainly in the form of soluble aggregate, but high-purity monomer rhIL-24 was obtained through size exchange chromatography with the addition of SDS in elution buffer. The tertiary structure of rhIL-24 was confirmed by fluorescence spectroscopy. Western blot analysis showed that rhIL-24 could be site-specifically modified by mPEG5000-ALD. Methyl thiazolyl tetrazolium (MTT) assay showed no significant difference between mPEG5000-ALD-rhIL-24 and rhIL-24 in inhibiting the growth of melanoma cell line A375 in vitro. Pharmacokinetic studies showed that PEG modification could significantly improve the stability and prolong the half-life of rhIL-24 from 8.41 to 13.2 h. The data strongly suggested that mPEG-ALD 5000 could site-specifically modify rhIL-24 expressed in E. coli. The PEG modification significantly prolonged the half-life of rhIL-24 without reducing its antitumor activity in vitro.

Citing Articles

Enhancement of recombinant human IL-24 (rhIL-24) protein production from site-specific integrated engineered CHO cells by sodium butyrate treatment.

Hua J, Xu H, Zhang Y, Ge J, Liu M, Wang Y Bioprocess Biosyst Eng. 2022; 45(12):1979-1991.

PMID: 36282328 PMC: 9719890. DOI: 10.1007/s00449-022-02801-0.

Protein Production and Purification of a Codon-Optimized Human NGN3 Transcription Factor from E. coli.

Narayan G, Agrawal A, Joshi N, Gogoi R, Nagotu S, Thummer R Protein J. 2021; 40(6):891-906.

PMID: 34550497 DOI: 10.1007/s10930-021-10020-x.

References

Lin L, Yamamoto R, Drummond R . Purification of recombinant human interferon beta expressed in Escherichia coli. Methods Enzymol. 1986; 119:183-92. DOI: 10.1016/0076-6879(86)19028-8. View

Wei S, Cao H, Zhou X, Wu H, Yang J . Prokaryotically and eukaryotically expressed interleukin-24 induces breast cancer growth suppression via activation of apoptosis and inhibition of tumor angiogenesis. Mol Med Rep. 2014; 11(5):3673-81. DOI: 10.3892/mmr.2014.3136. View

Gupta P, Su Z, Lebedeva I, Sarkar D, Sauane M, Emdad L . mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther. 2006; 111(3):596-628. PMC: 1781515. DOI: 10.1016/j.pharmthera.2005.11.005. View

Jiang H, Lin J, Su Z, Goldstein N, Fisher P . Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene. 1995; 11(12):2477-86. View

Pisal D, Kosloski M, Balu-Iyer S . Delivery of therapeutic proteins. J Pharm Sci. 2010; 99(6):2557-75. PMC: 2857543. DOI: 10.1002/jps.22054. View

Ellerhorst J, Prieto V, Ekmekcioglu S, Broemeling L, Yekell S, Chada S . Loss of MDA-7 expression with progression of melanoma. J Clin Oncol. 2002; 20(4):1069-74. DOI: 10.1200/JCO.2002.20.4.1069. View

Zhai Y, Zhao Y, Lei J, Su Z, Ma G . Enhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weight. J Biotechnol. 2009; 142(3-4):259-66. DOI: 10.1016/j.jbiotec.2009.05.012. View

Fisher P . Is mda-7/IL-24 a "magic bullet" for cancer?. Cancer Res. 2005; 65(22):10128-38. DOI: 10.1158/0008-5472.CAN-05-3127. View

Huang E, Madireddi M, Gopalkrishnan R, Leszczyniecka M, Su Z, Lebedeva I . Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene. 2001; 20(48):7051-63. DOI: 10.1038/sj.onc.1204897. View

10.

Wang Y, Liu Y, Chen J, Hao S, Hu T, Ma G . Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli. Int J Pharm. 2009; 386(1-2):156-64. DOI: 10.1016/j.ijpharm.2009.11.016. View

11.

Ma Q, Jin B, Zhang Y, Shi Y, Zhang C, Luo D . Secreted recombinant human IL-24 protein inhibits the proliferation of esophageal squamous cell carcinoma Eca-109 cells in vitro and in vivo. Oncol Rep. 2016; 35(5):2681-90. DOI: 10.3892/or.2016.4633. View

12.

Cohan R, Madadkar-Sobhani A, Khanahmad H, Roohvand F, Aghasadeghi M, Hedayati M . Design, modeling, expression, and chemoselective PEGylation of a new nanosize cysteine analog of erythropoietin. Int J Nanomedicine. 2011; 6:1217-27. PMC: 3131188. DOI: 10.2147/IJN.S19081. View

13.

Caudell E, Mumm J, Poindexter N, Ekmekcioglu S, Mhashilkar A, Yang X . The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol. 2002; 168(12):6041-6. DOI: 10.4049/jimmunol.168.12.6041. View

14.

Wang Y, Hao S, Liu Y, Hu T, Zhang G, Zhang X . PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: a comparison with glycosylated erythropoietin. J Control Release. 2010; 145(3):306-13. DOI: 10.1016/j.jconrel.2010.04.021. View

15.

Wang J, Hu T, Liu Y, Zhang G, Ma G, Su Z . Kinetic and stoichiometric analysis of the modification process for N-terminal PEGylation of staphylokinase. Anal Biochem. 2010; 412(1):114-6. DOI: 10.1016/j.ab.2010.12.030. View

16.

Sauane M, Gupta P, Lebedeva I, Su Z, Sarkar D, Randolph A . N-glycosylation of MDA-7/IL-24 is dispensable for tumor cell-specific apoptosis and "bystander" antitumor activity. Cancer Res. 2006; 66(24):11869-77. DOI: 10.1158/0008-5472.CAN-06-1887. View

17.

Chada S, Mhashilkar A, Liu Y, Nishikawa T, Bocangel D, Zheng M . mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: correlation with expression of bcl-2 family members. Cancer Gene Ther. 2005; 13(5):490-502. DOI: 10.1038/sj.cgt.7700915. View

18.

Yacoub A, Mitchell C, Hong Y, Gopalkrishnan R, Su Z, Gupta P . MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol Ther. 2004; 3(8):739-51. DOI: 10.4161/cbt.3.8.968. View

19.

Kreis S, Philippidou D, Margue C, Rolvering C, Haan C, Dumoutier L . Recombinant interleukin-24 lacks apoptosis-inducing properties in melanoma cells. PLoS One. 2007; 2(12):e1300. PMC: 2110900. DOI: 10.1371/journal.pone.0001300. View

20.

He X, Yin H, Wu J, Zhang K, Liu Y, Yuan T . A multiple-dose pharmacokinetics of polyethylene glycol recombinant human interleukin-6 (PEG-rhIL-6) in rats. J Zhejiang Univ Sci B. 2011; 12(1):32-9. PMC: 3017414. DOI: 10.1631/jzus.B1000085. View